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Abstract Postmenopausal osteoporosis is mainly caused by
increased bone remodeling resulting from estrogen deficien-
cy. Indications for treatment are based on low areal bone
mineral density (aBMD, T-score≤−2.5), typical fragility
fractures (spine or hip), and more recently, an elevated 10-
year fracture probability (by FRAX®). In contrast, there is
no clear definition of osteoporosis nor intervention thresh-
olds in younger individuals. Low aBMD in a young adult
may reflect a physiologically low peak bone mass, such as
in lean but otherwise healthy persons, whereas fractures
commonly occur with high-impact trauma, i.e., without
bone fragility. Furthermore, low aBMD associated with
vitamin D deficiency may be highly prevalent in some
regions of the world. Nevertheless, true osteoporosis in the
young can occur, which we define as a T-score below −2.5
at spine or hip in association with a chronic disease known
to affect bone metabolism. In the absence of secondary
causes, the presence of fragility fractures, such as in verte-
brae, may point towards genetic or idiopathic osteoporosis.
In turn, treatment of the underlying condition may improve
bone mass as well. In rare cases, a bone-specific treatment
may be indicated, although evidence is scarce for a true
benefit on fracture risk. The International Osteoporosis
Foundation (IOF) convened a working group to review
pathophysiology, diagnosis, and management of osteoporo-
sis in the young, excluding children and adolescents, and
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provide a screening strategy including laboratory exams for
a systematic approach of this condition.
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Introduction
Osteoporosis is a systemic skeletal disease characterized by
low bone mass, microarchitectural deterioration of bone
tissue leading to enhanced bone fragility, and a consequent
increase in fracture risk [1]. In postmenopausal women,
osteoporosis is usually the result of accelerated bone turn-
over due to estrogen deficiency, whereas in aging women
and men, vitamin D insufficiency and secondary hyperpara-
thyroidism may further contribute to bone loss. In these
subjects, osteoporosis is diagnosed when their hip or spine
bone mineral density (BMD) is two and a half standard
deviations (SD) or more lower than the young adult mean
(T-score≤−2.5) [2, 3]. Together with prevalent fragility frac-
tures (typically spine or hip), T-scores equal to or below −2.5
are considered as clear indications for osteoporosis therapy,
although age and clinical risk factors that modulate fracture
probability may also have to be taken into account [4]. Several
national guidelines now recommend using FRAX® thresholds
(10-year fracture probabilities) as indications for treatment
decisions in women and men aged 50 and above [5–7]. On
the other hand, low bone mass in children and adolescents has
been defined as an areal bone mineral density (aBMD) more
than 2 SD below the age-adjusted mean value (Z-score<−2
SD) [8], and it has been recommended that bone fragility
should not be diagnosed on the basis of low bone mass alone
but requires the presence of fractures due to low trauma [9].
In contrast to childhood and postmenopausal/elderly sub-
jects, diagnosis and treatment of osteoporosis in young adults,
i.e., between 20 and 50 years of age, remain poorly defined.
The true difficulty resides in differentiating between those
young healthy individuals whose apparently low aBMD
reflects low peak bone mass in relation to their body size,
pubertal timing, genetic background, and environment during
growth [10–12], which does not necessarily represent a path-
ological condition, and those whomay truly have osteoporosis
with bone fragility at a young age, resulting from altered bone
modeling and/or remodeling during growth and/or thereafter.
The latter situation is most commonly associated with a
chronic disorder and may also occur as a genetic or idiopathic
condition. Distinguishing between these two situations can be
all the more difficult because up to 30% of young women and
50 % of young men have had fractures during childhood and
adolescence, usually traumatic but not uncommonly multiple
[13–16]. These fractures are associated with decreased bone
mass acquisition and lower peak bone mass in otherwise
healthy individuals [15], i.e., without an underlying patho-
physiological mechanism. It would, therefore, be inappropri-
ate to perform a DXA examination and to search for
secondary causes of osteoporosis in most young people with
prevalent fractures, unless the circumstances (low trauma),
frequency (over two fractures), and/or site of fractures (e.g.,
vertebrae) appear unusual.
To help clinicians address this conundrum, the International
Osteoporosis Foundation (IOF) convened a working group to
review pathophysiology, diagnosis, and treatment of osteopo-
rosis in the young and to outline a screening strategy including
laboratory exams for a systematic approach to this condition.
This approach requires, first, the exclusion of secondary
causes [17] and, eventually, the assessment of whether any
possible genetic disorders of bone fragility are involved [18].
Peak bone mass and pathophysiology of osteoporosis
in the young
Between 8 and 18 years of age, bone mineral content
(BMC) more than doubles, whereas the true volumetric
bone mineral density (vBMD) barely changes [19]. This
bone mass accumulation pertains primarily to an increase
in bone size (diameter) and cortical thickness by periosteal
apposition (modeling) and, to a lesser extent, to trabecular
bone formation and thickening [20]. Meanwhile, endosteal
surfaces undergo both modeling and remodeling in order to
achieve, approximately by the age of 20, bone mass, geom-
etry, and microstructure of the adult skeleton [21]. In turn,
peak bone mass is a major determinant of bone strength and
fragility throughout life. Hence, the increase in bone diam-
eter and mass in growing males, which occurs at approxi-
mately the same rate as in females but lasts longer, leading
to a 10–15 % greater peak bone mass on average, plays an
important role in explaining the lesser and later propensity
to fractures in aging men compared to women. Neverthe-
less, as a result of continuous bone remodeling, loss of
cortical and trabecular bone starts soon after peak bone mass
is achieved in both genders, albeit in variable proportions in
weight-bearing and nonweight-bearing bones [22–24], and
accelerates in women after menopause and in aging men.
Heredity, that is, the additive effects of genes and their
polymorphisms, accounts for 50 to 80 % of the variation in
bone mass and structure among individuals [25] and likely
contributes to some of the phenotypic differences between
the male and female skeleton [26]. Yet gene expression
depends on both the internal and external milieu, i.e., on
hormone levels, particularly gonadal steroids (puberty) and
the growth hormone (GH)–IGF-1 axis; nutrition, such as
calcium and protein intake; physical activity, particularly
load-bearing exercise; lifestyle; etc. [19]. So any disorder
appearing during growth that alters one or more of these
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parameters will exert a negative influence on bone modeling
and remodeling, affecting bone mass acquisition and its
distribution in the cortical and/or trabecular compartment,
and could thereby cause bone fragility not only during
growth but later on in young adults. Similarly, endocrine,
nutritional, and other disturbances appearing during early
adulthood will precipitate bone loss at a younger age. A
typical example would be inflammatory bowel diseases
(IBD), particularly Crohn's disease, which impair bone mass
accrual and/or accelerate bone loss because of malabsorp-
tion and poor nutrient intake, low levels of physical activity,
delayed puberty or secondary amenorrhea, in addition to
systemic inflammation and, in many cases, effects of corti-
costeroid treatment [8, 27]. Another good example of the
complex pathophysiology of osteoporosis in the young is
illustrated by thalassemia major, which causes hormonal
deficiencies (GH–IGF-1 and gonadal steroids), expands
bone marrow at the expense of bone tissue, interferes with
mineralization due to iron overload, and additionally, defers
oxamine treatment that inhibits osteoblastic function [28].
Among numerous pharmacological agents implicated in bone
loss (Table 1), depot progesterone acetate (Depo-Provera),
used as a contraceptive agent, has recently raised huge con-
cerns [29, 30].
Definition and prevalence of osteoporosis in the young
As long as peak bone mass has not been achieved, the T-
score definition of osteoporosis cannot be used. Hence, low
bone mass in children and adolescents has been defined by a
Z-score below −2, and this definition could be extended
beyond 20 years of age in those with delayed puberty, as
is often the case with chronic diseases from childhood [8, 9].
By extension and considering that in young adults T- and Z-
scores are virtually identical, the 2007 International Society
for Clinical Densitometry Official Positions has suggested
keeping the use of Z-scores to define “low bone mass” in
young adult (premenopausal) women [31]. For the sake of
coherence with the WHO operational definition of osteopo-
rosis, however, we propose to keep the T-score-based defi-
nition of the disease for young adults, unless it appears that
he/she is still growing. Hence, in young adults suffering
from a chronic disorder known to affect bone metabolism
(Table 1), a T-score below −2.5 at spine or hip should be
considered as diagnostic of osteoporosis. It is important to
note, however, that the relationship between aBMD and
fracture risk is not well established among young adults
and that fracture prediction tools, such as FRAX®, are not
valid for the young population. In the absence of secondary
causes, occurrence of fragility fractures, in addition to the
low T-score, may indicate genetic or idiopathic osteoporosis
(see below). Hence, the detection of prevalent vertebral
fractures, which in the absence of major back trauma most
likely indicate bone fragility, plays an important role in the
identification of young adults with osteoporosis. For this
purpose, DXA-based vertebral fracture assessment (VFA)
tools now appear as major add-ons to aBMD evaluation
[32].
According to a T-score≤−2.5, in theory, only 0.5 % of
young women aged 30–40 years would fulfil the criteria of
osteoporosis and another 15 % would be considered as
Table 1 Major causes of sec-
ondary osteoporosis in the
young
HIV human immunodeficiency
virus, MPA medroxyprogester-
one acetate (used as contracep-
tive), HAART highly active
antiretroviral therapy, PPIs pro-
ton pump inhibitors
Chronic and inflammatory Inflammatory bowel disease Malabsorption
Coeliac disease HIV
Nephropathies Organ transplant
Cystic fibrosis Connective tissue diseases
(Juvenile) rheumatoid arthritis Thalassemia
Systemic mastocytosis Leukemia
Endocrine Diabetes type I Cushing's syndrome
Hypovitaminosis D Hyperparathyroidism
Hypogonadism (amenorrhea, Turner,
anorexia nervosa)
Hyperthyroidism Pregnancy
Neuromuscular and metabolic Duchenne Galactosemia
Gaucher's disease Glycogen storage disease
Hemochromatosis Marfan syndrome
Medications Glucocorticoids Glitazones
PPIs (chronic use)
Anticonvulsants Cyclosporine (tacrolimus)
Aromatase inhibitors, depot MPA GnRH inhibitors
High-dose thyroxine Heparin (long-term)
Cytotoxic chemotherapy HAART
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osteopenic (T-score between −2.5 and −1) in any population
[33]. This is corroborated by several observations, including
a study of 282 premenopausal healthy women (mean age
34.8 years) without family history or secondary causes of
bone fragility, which reported osteopenia in 10.6 % of cases
[34]. Similar prevalence of low bone mass in 579 Spanish
premenopausal women (aged 20–44 years) was observed,
with lumbar spine (LS) BMD characterized as osteoporosis
and osteopenia in 0.3 % and 13.1 % of the cases, respec-
tively, and in 0.2 % and 12.6 %, respectively, using femoral
neck (FN) BMD [35].
Against this background of low prevalence of osteoporo-
sis in healthy young individuals, the prevalence of osteopo-
rosis and/or fragility (vertebral) fractures can reach 15 % to
50 % in young subjects with IBD [36–38], coeliac disease
[39–41], cystic fibrosis [42–44], type 1 diabetes [45–47],
rheumatoid arthritis [48], and anorexia nervosa [49–51],
among other causes of secondary osteoporosis (Table 1).
Clinical approach of osteoporosis in the young
As mentioned above, young individuals suffering from a
chronic disease (Table 1) and/or presenting with a low trauma
fracture, particularly in vertebrae, and/or multiple fractures
(more than two) should have a DXA (ideally combined with
VFA) evaluation. For those individuals with a T-score<−2.5
and/or fragility fractures but no known secondary cause, a
search for underlying disorders and/or medications potentially
associated with osteoporosis should be initiated (Fig. 1). Low
aBMD alone and/or together with bone and muscle pain (and
weakness in the latter) can be due to vitamin D deficiency,
eventually osteomalacia, i.e., not necessarily osteoporosis.
Moreover, when vitamin D levels are adequate, low aBMD
without fragility fractures, including the absence of vertebral
crush fractures as evaluated by VFA (see above) and/or lateral
X-rays, does not necessarily represent a pathological situation,
particularly in subjects of small body size [8]. Investigations
in this case should be limited in the absence of symptoms and/
or signs of a chronic disorder. Interestingly, in one study of
constitutionally lean1 young women without menstrual alter-
ations, aBMD as well as trabecular and cortical microstructure
at distal radius was found to be as low as in women with
anorexia nervosa, and the calculated bone breaking strength of
the constitutionally lean was lower than normal [54]. Al-
though low aBMD in a particularly lean (BMI<18.5 kg/
cm2) but healthy individual could, therefore, represent an
increased risk of fractures, there is no evidence, so far, for
any therapeutic intervention in these cases. Similarly, late
puberty has been associated with decreased peak bone mass,
radius cortical vBMD, and thickness [55], but again, there is
no evidence that this situation should prompt further inves-
tigations nor a therapeutic intervention in the absence of
symptoms and/or signs for an underlying chronic disorder.
In contrast, osteoporotic patients with low body mass index
(<18.5 kg/cm2 as underweight defined by WHO) and men-
strual (for women), eating, and/or behavioral disorders must
be investigated for the possibility of secondary osteoporosis
(more specifically anorexia nervosa).
Some series indicate that in 44–90 % of young men and
women with osteoporosis or clinical fractures, an underlying
secondary cause can be determined (see Table 1) [56–58], and
the large percentage gap between studies probably reflects
more or less intensive searches to determine the cause of
osteoporosis and/or different referral patterns. In practice, this
search should include a complete medical history, including
personal and a thorough family history (see genetic causes
below) of bone fragility and/or endocrine, metabolic and
inflammatory disorders, past and present medications, age of
menarche and/or history of amenorrhea, food intolerance,
abdominal pain and bowel movements, urticaria, timing of
recent pregnancies and lactation, and dietary and exercise
patterns. Physical examination should particularly consider
low height and/or BMI (see reasons above), abdominal ten-
derness, cutaneous signs of allergy (urticaria), hyperpigmen-
tation or decreased pilosity (hypogonadism), as well as the
presence of kyphosis, limb deformities, joint inflammation,
hyperlaxity, blue sclerae, and/or poor dentition.
Laboratory tests
A set of laboratory tests to screen for the most common bone
and mineral disorders (including vitamin D deficiency and
primary hyperparathyroidism), thyroid dysfunction, diabe-
tes, renal failure and hepatic dysfunction, systemic inflam-
mation, and in men, hypogonadism (particularly in the
presence of other clinical signs) is presented in Table 2. It
is particularly important to discard the possibility of vitamin
D deficiency (25OHD<10 ng/ml or 25 nmol/L), as this may
affect bone mineralization and be translated into low aBMD,
without being osteoporosis.
It is worth noting that coeliac disease (prevalence 1 %)
may present in occult form, particularly since most adults
will change their diet to avoid food intolerance/bowel symp-
toms, and should be suspected especially in the presence of
low 25-hydroxyvitamin D. An elevated titer of antiendomy-
sial or antitissue transglutaminase Ab has an excellent
1 Constitutional thinness (CT), or Leanness, was identified over the last
decades as a nonpathological state of underweight that does not meet
the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV
criteria of anorexia nervosa. Contrary to the later pathology, the non-
pathological state of CT in adult women is supported by the presence
of menstruations, normal thyroid and cardiac functions, and normal
insulin sensitivity. Moreover, CT individuals are characterized by a
body weight that has always been in the lower percentiles for age,
gender, and ethnicity. Familiality and heritability of thinness were also
described or demonstrated. For further reading, see [52–54].
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positive predictive value for this disease [59]. Note that
diagnosis of IBD (Crohn's disease and ulcerative colitis) is
commonly delayed up to 2 years after the appearance of the
first digestive symptoms. Hence, patients with low bone
mass/bone fragility and abdominal symptoms/signs who test
negative for antitissue transglutaminase Ab (and who may
have inflammatory markers) should be referred to a special-
ist for further intestinal investigations.
An additional set of selected diagnostic tests to be applied
when the clinical and/or first laboratory results orient to-
wards a specific condition is shown in Table 3. Although
systemic mastocytosis (SM) is a rare (0.3/10,000) condition,
it is diagnosed in 0.4 to 1 % of bone biopsies referred for the
investigation of osteoporosis [60], and an even higher prev-
alence has sometimes been reported. It becomes clinically
manifest as urticaria pigmentosa in 60 % of the patients,
gastrointestinal manifestations in 40 %, and idiopathic ana-
phylactoid reactions in 20 %. However all of these symp-
toms can be absent and the skeletal manifestation can be
isolated, with osteoporosis in up to 30 % of patients with
SM [61, 62]. An elevated serum tryptase (>20 ng/ml) has a
positive predictive value of 98 % for SM [61].
Besides bone alkaline phosphatase (BALP) which levels,
if high after growth is completed, can orient towards
osteomalacia (together with low 25OHD levels), Paget's
disease, or bone neoplasia, and if low, towards hypophos-
phatasia (see below), the utility of bone turnover markers
(BTMs)—that is, procollagen peptides (N and C terminals,
PINP, and PICP, respectively) for bone formation and telo-
peptide cross-links of collagen type I (N and C terminals,
NTX, and CTX, respectively), deoxypyridinoline/pyridino-
line, and tartrate-resistant acid phosphatase for bone resorp-
tion—in the investigation of osteoporosis in the young
remains controversial [63] (for reference range in young
women, see [64]). First, data demonstrating a predictive role
of BTMs for fracture risk in secondary osteoporosis are lack-
ing, although they have been correlated with BMD changes in
some diseases (i.e., IBD) [65]. Second, BTMs are correlated
with the level of 25OHD, IGF-1, physical activity, etc.
[66–69], and in the case of a chronic disorder, BTMs can be
elevated, normal, or low depending on the nature of the
underlying disease, its severity and relapses, past and current
therapy, as well as the subject's mobility and nutrition. In
premenopausal women with idiopathic osteoporosis, bone
turnover may also be high, normal, or low [70]. BTMs have
been negatively correlated with HbA1C in type 1 diabetes,
i.e., were lower with poor glucose control [71]. In contrast,
when the achievement of peak bone mass is delayed, as is
Laboratory Tests - General Screening (Table 2)
Negative Test 
Consider extended referrals
Imaging and/or Biopsies  
(gut, skin, bone marrow, bone) 
Laboratory Tests – Selected Conditions
(Table 3) 
Assume
Low Peak Bone Mass 
Positive Test 
Abnormal BTM Normal BTM 
Medical history and physical examination
(exclude medication associated with bone loss) 
Constitutional leanness  
or late puberty 
Idiopathic or genetic 
osteoporosis: 
See Figure 2 
LOW aBMD (T-sc. < -2.5 spine or hip)
&/or VERTEBRAL FRACTURE &/or MULTIPLE FRACTURES 
Measure Bone Turnover Markers 
Repeat DXA scan 
(after 2 years) 
Stop
investigation 
and reassure
Negative Test Positive Test 
Refer to disease 
specialist 
Negative Test Positive Test 
Targeted therapy 
Fig. 1 Clinical pathway for
determining the cause of bone
fragility in young adults with low
BMD, vertebral fracture, and/
or multiple fractures
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often the case with chronic disorders starting during childhood
or adolescence, BTMs may remain elevated into young adult-
hood (between 20 and 25 years of age) as a reflection of the
ongoing physiological bone modeling/remodeling state rather
than a catabolic state. A recent fracture may also cause an
elevation of BTMs for several months. Note that in patients
with osteogenesis imperfecta (OI), PINP, and ß-CTX are
normal or low, whereas osteocalcin is normal or high, reflect-
ing the alterations in collagen metabolism on one side and
bone turnover on the other side [72].
Despite these difficulties in interpreting BTMs, nor-
mal BTMs in a young adult with low aBMD would
argue for an acquired low peak bone mass, whereas
high BTMs would point towards an ongoing process
of bone loss, as seen, for instance, in anorexia nervosa
compared to constitutionally lean women [54]. Taken
together with a low T-score and some evidence of bone
fragility (see above), elevated BTMs could, therefore,
prompt further investigations for an underlying cause
(Fig. 1) and could be useful for therapeutic guidance [73].
On the other hand, low bone turnover has been ob-
served in a subset of young women with idiopathic
osteoporosis in association with a more pronounced
deficit in bone microarchitecture and stiffness [70].
Genetic osteoporosis
A thorough family history of bone fragility should always
be considered when investigating osteoporosis in the young,
in particular for those individuals with extremely low bone
mass and/or multiple fractures. In the absence of secondary
causes, an autosomal-dominant or autosomal-recessive mu-
tation could indeed be responsible for bone fragility (Fig. 2).
To date, there are more than 300 monogenic disorders with
Table 3 Laboratory tests—selected conditions
Background Test
TSH alterations Free T4
Altered glucose, Cushing's syndrome 24-h free urinary cortisol
Altered testosterone (men) LH/SHBG (free testosterone)
Amenorrhea, hypogonadism (women) FSH/estradiol
Altered renal function (CRF) 1,25(OH)2D3
Hemochromatosis Ferritin
Hypophosphatasia ALP, BALP, urinary
phosphoethanolamine
Mastocytosis Tryptase, IgE
Gaucher's disease Glucocerebrosidase
TSH thyroid-stimulating hormone, LH/SHBG luteinizing hormone/sex
hormone-binding globulin, FSH follicle-stimulating hormone, CRF
chronic renal failure, BALP bone-specific alkaline phosphatase, IgE
immunoglobulin E
Table 2 Laboratory tests—general screening
Mineral metabolism Serum calcium (corrected for
albumin)
Serum phosphate
Creatinine
25(OH)D
iPTH
ALP (bone specific)
BTMs (for instance, s-CTX and
s-PINP)a
Inflammation, hematopoietic
disorder
Blood cell count
ESR or CRP
Hepatic disease GOT, GPT, γ-GT
Diabetes (primary or secondary) Fasting glucose, Hba1C
Thyroid dysfunction TSH
Hypogonadism (men) Total testosterone
Malabsorption, Coeliac disease 24-h urinary calcium
Anti-endomysial, anti-
transglutaminase
25OHD 25-hydroxyvitamin D, iPTH intact parathyroid hormone, ALP
alkaline phosphatase, BTM bone turnover markers, s-CTX serum
carboxy-terminal cross-linking telopeptide of type I collagen, s-PINP
serum procollagen type I N propeptide, ESR erythrocyte sedimentation
rate, CRP C-reactive protein, GOT glutamic oxalacetic transaminase,
GPT glutamic pyruvic transaminase, γ-GT γ-glutamyltransferase, TSH
thyroid-stimulating hormone
a See text for details
Family Screen 
(First degree relatives) 
For BMD and Multiple Fractures 
Osteogenesis Imperfecta 
OPPG
Other Gene Mutation, Carrier (Table 4) 
Genetic Testing  
Mendelian Inheritance Non-Mendelian Inheritance 
True Idiopathic osteoporosis 
(Polymorphism) 
or
New Gene Mutation 
LOW BMD &/or VERTEBRAL FRACTURE &/or MULTIPLE FRACTURES 
+
No Secondary Causes, no Constitutional Leanness, No Late Puberty 
Suspect 
•
•
•
Fig. 2 Clinical pathway for young adults, with either low BMD and/or
vertebral fracture, and/or multiple fractures, where no secondary causes
of osteoporosis (including constitutional leanness and delayed puberty)
were found
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skeletal manifestations [74], including a number associated
with bone fragility, such as connective tissue (OI and Mar-
fan), lysosomal storage (Gaucher's and Pompe disease), and
endocrine syndromes (including hypogonadotrophic hypo-
gonadism, estrogen receptor, and aromatase mutations in
men) [75–77]. However, skeletal complications are usually
neither the first nor the predominant manifestations in most of
these diseases, with the exception of OI, hypophosphatasia
[78], and osteoporosis-pseudoglioma (OPPG) (Table 4), the
latter also characterized by presence of congenital or infancy-
onset blindness [79]. In nonosteoporotic young adults with
repeated low-trauma fractures (including vertebral fractures)
and no secondary causes, mild forms of OI should be excluded
(genetic screening of Col1A1 and Col1A2 mutations) [80].
Idiopathic osteoporosis in the young
A particular situation occurs in young men with idiopathic
osteoporosis, i.e., after secondary causes including hypogo-
nadism, alcoholism, and medications have been excluded.
These men are characterized by lower body weight and
lower aBMD most prominent at the LS, reflecting low
(trabecular and cortical) vBMD and smaller bone size. Long
bone cortices are thinner due to larger endosteal cavities.
Vertebral fractures, which are common in idiopathic male
osteoporosis (IMO), have been associated with increased
cortical porosity on iliac crest bone biopsies [81]. In these
men, there is usually no evidence of either accelerated bone
loss or increased bone turnover. Overall, the data points
toward a defect in bone formation leading to decreased bone
mass acquisition [82]. Lower circulating levels of IGF-1 and
(free or bioavailable) estradiol, and higher SHBG could play
a role in IMO. Moreover, there is a strong familial and
genetic component involved, with a substantial proportion
of sons being affected. Functional gene polymorphisms in
the LDL-receptor-related protein 5 gene (LRP5) have been
associated with this condition [83].
Idiopathic osteoporosis also exists in premenopausal
women, but its pathophysiology is less well understood. A
recent bone biopsy study in 45 premenopausal women with
fragility fractures, 19 with low aBMD and 40 controls,
indicates that the group with idiopathic osteoporosis has
significantly thinner cortices and trabeculae, and a lower
mean wall thickness, i.e., a bone formation deficit [70].
However, bone turnover and indices of bone remodeling
are extremely heterogenous in these women. Only in a
subgroup with low bone formation rate and more severely
disrupted microarchitecture were serum IGF-1 levels elevat-
ed, suggesting a resistance against this growth factor. In
another study, young women with idiopathic osteoporosis
were reported to have lower free estradiol levels and higher
bone turnover than normal [84]. It should be noted that
hypercalciuria may be present not just in a subset of men,
but also in premenopausal women with idiopathic osteopo-
rosis [85].
Osteoporosis in pregnancy and lactation
A moderate increase of bone turnover has been observed
during pregnancy [86], although it is still uncertain whether
significant changes of bone mass occur. A small decrease in
aBMD has been observed at the LS, but in long bones, this
might be compensated by endosteal and periosteal appositions
[87]. While during pregnancy the mother's intestinal calcium
absorption is increased, during lactation, it returns to normal
values [88], putting further pressure on the skeleton to com-
pensate for the need of calcium associated with breastfeeding.
The body adapts by increasing bone resorption and reducing
renal calcium excretion, influenced by increase in PTHrP
production and hypoestrogenic state secondary to high pro-
lactin levels [87, 89, 90]. The decrease in bonemass, observed
mainly in the trabecular compartments of bones, is generally
restored 6 to 12 months after weaning [91].
Pregnancy-associated osteoporosis is a rare condition,
which can present in the form of spinal osteoporosis or
transient osteoporosis of the hip (TOH), as well as associat-
ed with prolonged heparin use [92]. TOH is associated with
uni- or bilateral hip pain and may be complicated with a
fracture, sometimes spontaneous [93]. Postpregnancy oste-
oporosis can lead to vertebral fractures, height loss, and
severe back pain [94], as well as clinical fractures at other
sites. Preexisting low BMD and high bone turnover during
pregnancy and lactation may both play a role [89]. In
women of reproductive age with established osteoporosis,
it could, therefore, be recommended to avoid breastfeeding.
Note that in a randomized double-blind placebo-controlled
study on postpartum healthy women, calcium supplementa-
tion did not prevent bone loss during lactation and only
slightly enhanced gain in bone density after weaning [95].
Treatment of osteoporosis in the young
Once vitamin D deficiency has been ruled out and/or cor-
rected (i.e., 25OHD levels≥20 ng/ml or 50 nmol/L), the
approach to osteoporosis in the young should primarily
target the underlying disorder. Since the mechanisms lead-
ing to secondary osteoporosis in the young are rarely unique
(see IBD, for instance [27]), interventions should be multi-
factorial, i.e., target vitamin and nutritional deficiencies,
particularly vitamin D, calcium and protein intake, physical
activity, inflammation, corticosteroid treatment, and/or gonad-
al steroids. With vitamin D insufficiency being such a com-
mon finding in most subjects with secondary osteoporosis,
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vitamin D supplementation (1,000–2,000 IU) should be
given first, prior to eventually considering any bone-
specific drug (see below), since it has the potential to
improve aBMD by restoring proper bone matrix miner-
alization, preventing secondary hyperparathyroidism and
moderate bone turnover. In contrast with their beneficial
effects in secondary osteoporosis, there is little evidence
that general measures such as physical exercise, calcium
and vitamin D supplementation improve bone mass in
young adults with idiopathic osteoporosis. Furthermore,
there is no evidence for the use of bone-specific drugs
in this context.
Small and often poorly controlled studies have shown
that specific interventions to target the primary disease
in turn have beneficial effects on aBMD, although data
on fracture prevention are virtually nonexisting (Appendix).
Among those targeted interventions are TNF inhibitors,
such as infliximab in IBD [96, 97] and rheumatoid arthritis
[98], and gluten-free diet in coeliac disease [99]. Ade-
quate iron chelation with more recent iron chelator, i.e.,
not deferoxamine, and hormonal substitution of hypogo-
nadism may have beneficial effects in thalassemia major
[28]. Besides the favorable effects of weight recovery in
anorexia nervosa, the role of hormone therapy (HT)±IGF-1
remains controversial [100]. In a meta-analysis of pro-
spective cohort studies and randomized clinical trials,
HT in young women with anorexia nervosa significantly
improved LS BMD, but to a lesser extent, FN BMD
[101]. Contrasting with the improvement of bone mass
associated with the treatment of most secondary causes
of osteoporosis, administration of antiretroviral therapy
(ART) for HIV, particularly tenofovir, can further ag-
gravate bone loss and fracture risk in these patients
[102].
Evidence is limited to recommend bone-specific drugs,
such as bisphosphonates (BPs) in young adults with sec-
ondary osteoporosis. Young women with anorexia nerv-
osa and treated with daily risedronate had significant
improvements of LS BMD after 6 and 9 months com-
pared to a control group, although no changes occurred
for total body and hip BMD [103]. Bone loss can also
be reduced in premenopausal women who develop
chemotherapy-induced amenorrhea using selective estro-
gen receptor modulators (SERMs) or BPs [104–107].
LS BMD was improved with risedronate and zoledronic
acid in young women with ovarian failure after alloge-
neic stem cell transplant, which was not observed with
HT alone [108]. Young endometriotic women treated
with gonadotropin-releasing hormone (GnRH) agonists
are also prone to bone loss due to severe estrogen
deprivation. In these subjects, BMD levels can be sta-
bilized and even increased at some skeletal sites by
combining GnRH treatment with ‘add-backs’ such as
human parathyroid hormone (hPTH-1-34), HT, or dana-
zol [75, 109]. BPs given with infliximab have been
shown to improve BMD in patients with Crohn's dis-
ease [97], and alendronate and zoledronate to increase
aBMD in cystic fibrosis [110–112]. Calcitonin and most
Table 4 Main monogenic disorders primarily manifest as bone fragility
Monogenic disorders Gene mutations Familial pattern of
inheritance
Description and main clinical
outcome
Incidence
Osteogenesis
imperfecta
Col I α1 and Col I α2 Autosomal dominant
(types I–V)
Fragility fractures, bone
deformity, and low BMD
Estimated at 6 to 7 per 100,000
people worldwide
LEPRE1 and CRTAP
(some OI types II, III,
and VII)
Autosomal recessive
(some types II, III, VII,
and IX)
Dentinogenesis imperfecta Types I and IV are the most
common forms, affecting 4 to
5 per 100,000 people
PPIB in type IX Mild forms may be manifest as
low aBMD only
Hypophosphatasia ALPL Autosomal dominant
(adult form)
Defective mineralization, leading
to softening of the bones
(osteomalacia)
Severe forms affect an
estimated 1 in 100,000
newborns. Milder cases, such
as those that appear in
adulthood, probably occur
more frequently
Autosomal recessive
(perinatal)
Recurrent fractures in the foot and
thigh bones inducing chronic
pain
Loss of adult teeth prematurely
Joint pain and inflammation
Osteoporosis-
pseudoglioma
syndrome (OPPG)
LRP5 (11q13.4) Recessive Fragility fractures, bone
deformity, low BMD and partial
blindness
Unknown
Carrier state may be manifest as
bone fragility only
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BPs can decrease bone turnover and bone pain and improve
aBMD in thalassemia major [28]. Two small randomized
clinical trials of zoledronic acid (4 mg i.v. every 3 months)
have shown increases of aBMD in this disease [113, 114], and
a meta-analysis including five studies but only 100 patients
also indicates beneficial effects of zoledronic acid on aBMD
(LS > FN) in thalassemia major [115]. In ten patients with SM
and osteoporotic fractures, the combined effects of interferon
alpha and monthly pamidronate (1 mg/kg) increased LS BMD
by 12.6 % and hip BMD by 1.9 % per year and no fractures
developed under treatment [116]. Whether BPs dosing higher
than usually prescribed in osteoporosis is actually required for
patients with thalassemia major or SM, however, remains
poorly substantiated, as the long-term effects of BP therapy
in these young individuals have not been evaluated. In HIV-
associated osteopenia and osteoporosis (mostly men), two
small RCTs of, respectively, zoledronate once yearly and
alendronate once weekly have shown significant improve-
ments of aBMD [117–119]. It is, however, questionable if
HIV-infected patients with osteopenia and without evidence
of fragility fractures should receive an antiresorptive therapy.
A discussion about the utility of BPs in OI is beyond the scope
of this review (see reviews [120, 121]).
Certain BPs, as well as teriparatide, have been shown to
reduce bone loss in glucocorticoid-induced osteoporosis,
and several guidelines have been recently developed to
address this topic [122–124]. The evidence of their effect
on fracture risk reduction in premenopausal women and
men is scarce. However, as reported by the IOF-ECTS
recommendations, bone protective therapy may be appro-
priate in some premenopausal women and younger men,
particularly in individuals with a previous history of fracture
or those receiving high doses of glucocorticoids [124].
There is an important concern about the risk of
congenital malformations with the administration of
BPs in women of childbearing age [125] and teripara-
tide is contraindicated in pregnancy. On the other side,
several case reports in mothers and their infants have
demonstrated the safety of BPs during pregnancy and
lactation [126–130]. Contrasting results exist on the
improvement of LS BMD and reduction of future frac-
ture risk in pregnancy-associated osteoporotic women
[131]. This small retrospective study on pregnant and
lactating women, where BMD levels at baseline were
low (FN −2 SD and LS −2.8 SD on average), attempted
to look at the effects of certain BPs on fracture rate and
BMD, but the study was largely underpowered [131].
Generally, caution must be taken in prescribing BPs to
reproductive women, since BPs are known to be stored
and released from bones for long periods of time and have
shown to affect fetal skeletal ossification in rat models [132,
133]. Their effect on bone growth in infants in the long-term is
still unknown.
Conclusions and perspectives
The diagnosis of osteoporosis in the young presents
several challenges, since low bone mass and/or periph-
eral fractures with high-trauma are not necessarily asso-
ciated with skeletal fragility. An apparently low aBMD
(T-score<−2.5 at spine or hip by DXA) must be inter-
preted with caution in young individuals of small body
size (constitutionally lean) and/or stunted growth. It
should be emphasized that an inaccurate ‘diagnosis’ of
osteoporosis in young subjects can lead to anxiety, unneces-
sary drug prescriptions, and in some countries, potential
restrictions of insurance coverage. Thus, subjects with
isolated low bone mass, although possibly deserving
investigation depending on the context, for instance, to
rule out vitamin D deficiency in regions of the world
where this condition may be endemic, should not be
classified as osteoporotic, and this diagnosis should be
reserved for those subjects with evidence of skeletal
fragility. Nevertheless, a truly low BMD and/or unusual
fractures (such as low-trauma, multiple and vertebral)
should prompt investigation for secondary causes of
osteoporosis. Careful medical history, clinical, and lab-
oratory investigations can reveal an underlying disease
(mostly inflammatory, metabolic, and/or associated with
gonadal insufficiency) that is amenable to specific med-
ical interventions, which, in turn, will improve bone
mass. BPs may improve BMD in young subjects with
osteoporosis due to various disorders; however, the ev-
idence is scarce so far, since the available studies were
small, of limited duration, and there are no data on their
antifracture efficacy. In any case, the indications and
duration of antiresorptive treatment in the young should
be as restrictive as possible, particularly in the absence
of secondary causes (such as idiopathic osteoporosis,
which may result from low peak bone mass rather than
accelerated bone loss), multiple and/or fragility (verte-
bral) fractures, and high bone turnover accompanied by
documented bone loss.
Ongoing developments of noninvasive technologies
that can measure vBMD and bone microstructure in
the cancellous and cortical bone compartments, such as
high-resolution pQCT and derived estimates of bone
strength (by finite element analysis), in the future could
help the clinician to better evaluate the structural bases of bone
fragility in the young [55, 134].
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Appendix A. Effects of treatments (specific and bone
drugs) on the various diseases
Secondary disease Treatment Benefits on bone Reference
Inflammatory bowel
disease: Crohn's disease
Infliximab Tibia trabecular BMD and endosteal circumference Z-scores
improved significantly over 12 months in children with
Crohn's disease
[135]
Infliximab LS BMD: +8.13 % after 1 year follow up compared to baseline,
vs. only +1.55 % in the control group (p<0.01)
[96]
Infliximab +
bisphosphonates
LS BMD: +6.7 %/year in patients on concurrent treatment
vs. +4.46 %/year in those on oral bisphosphonates alone
(p00.045) over 2.2+0.99 years
[97]
Celiac disease Gluten-free diet 4 % increase in LS and FN BMD after 1 year compared to
baseline and up to 8 % for trochanter BMD. Lower values
after 5-year follow-up
[99]
Cystic fibrosis Alendronate After 1 year of alendronate (70 mg once weekly for 1 year),
BMD increased at the lumbar spine (5.2 % vs. −0.1 %) and at
the hip (2.1 % vs. −1.3 %) compared with controls
[111, 112]
Zoledronic acid Compared with controls, LS BMD in zoledronic-treated group
(2 mg i.v. every 3 months for 2 years) increased from baseline
at 1 year (6.6 % vs. 0.35 %) and 2 years (6.14 % vs. 0.44 %),
and femoral neck BMD increased at 1 year (4.12 % vs.
−1.59 %) and 2 years (4.23 % vs. −2.5 %)
[110]
Adjuvant endocrine therapy
for hormone-responsive
breast cancer
Zoledronic acid Zoledronic acid (4 mg intravenously every 6 months for
3 years) prevented bone loss at the spine and hip
[104, 136]
Risedronate In contrast to a significant decrease of BMD at the lumbar spine
and hip in the placebo group, there was an increase in BMD in
the risedronate group (30 mg/d, oral for 2 weeks, followed by
10 weeks without drug, repeated 8 times over 2 years). At
2 years, the mean difference (±SEM) between groups was
2.5 %±1.2 % at the lumbar spine (p0 .041) and 2.6 %±
1.1 %, (95 % CI, 0.3 to 4.8) at the femoral neck (p0 .029)
Ovarian failure after
allogeneic stem cell
transplantation
Various (Ca + Vit. D;
HRT, risedronate,
zoledronic acid)
At 1 year, a significant decrease in LS and FN BMD was
observed for the Ca + Vit. D group and a milder decrease in
the HRT group. Risedronate treatment increased significantly
LS BMD and prevented FN BMD loss. Zoledronic acid
increased significantly both LS and FN BMD
[108]
Anorexia nervosa Menstrual recovery Stabilization of BMD with menstrual recovery [137]
Recombinant human
IGF-I and HRT
BMD increased in women treated with rhIGF-I and HRT
(1.8 %) vs. rhIGF-I alone (0.3 %)
[100]
Risedronate Increase of spine BMD of 4.9±1.0 % at 9 months (5 mg daily),
even without significant weight gain
[103]
Alendronate Body weight was the most important determinant of BMD after
1 year of alendronate (10 mg/d oral)
[138]
Chemo-induced amenorrhea Tamoxifen At 3 years of follow-up, in amenorrheic patients who developed
chemotherapy-induced early menopause, the LS BMD de-
creased −6.8 % in tamoxifen users and −9.5 % in the controls
[107]
Pamidronate At 1 year of follow-up of pamidronate (60 mg i.v. every
3 months), in amenorrheic patients who developed
chemotherapy-induced early menopause, the LS BMD in-
creased 1 % in tamoxifen users and decreased −4 % in the
controls
[105]
Rheumatoid arthritis Infliximab At 1 year of follow-up, BMD loss was significantly reduced in
the infliximab group compared with the placebo group at the
femoral neck (−0.35 % vs. −3.43 %) and total hip (−0.23 %
vs. −2.62 %) but not at the hand and spine
[98]
HIV Alendronate Alendronate (70 mg weekly for 96 weeks) increased BMD at
sites with a T-score<−2.5 by 7.1 % vs. 1.0 % in the placebo
(p00.0003)
[119]
Zoledronic acid Bone density improved in a 12-month trial of 5 mg intravenous
zoledronate compared to placebo
[118]
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